*This product has not been approved by the FDA
Here are some common scenarios: Initial Treatment Phase: In the initial phase of treatment, injections may be administered more frequently, such as daily or weekly, until B12 levels are restored
As Provincial Technical Center, Veyong has established an innovated R&D system for new veterinary
Areas Without Adequate Human Evidence Cardiovascular safety Neurological and psychiatric effects Liver and kidney safety Effects on blood glucose in humans Effects on methylation pathways Genotoxicity Carcinogenicity Reproductive and developmental toxicity Use during pregnancy or breastfeeding Interactions with prescription medicines Interactions with supplements or research compounds Long-term exposure Product-Quality Risks Incorrect quinolinium compound Wrong substitution position Incorrect counterion Incorrect active-content calculation Residual starting materials Residual solvents Degradation products Heavy-metal or inorganic contamination Mismatched certificate of analysis Uncontrolled storage and transport Absence of published harm is not proof of safety A compound without routine regulated human exposure may generate very few formal safety reports simply because there is no organised pharmacovigilance system
Exposing B12 solution to light
The injections can create problems in various body parts like the heart, lungs, skin, brain, and muscles
